Streetbeat News

DYN

Dyne Therapeutics, Inc.

Industry

Biotechnology

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Open

28.89

Mkt cap

Volume

650K

High

29.69

P/E Ratio

-8.29

52-wk high

47.45

Low

28.13

Div yield

N/A

52-wk low

10.03

Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating for Dyne Therapeutics, maintaining a price target of $55.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 5:52 pm

Recursion Pharmaceuticals shares fell 11.6% after announcing Phase 2 data for a treatment for Cerebral Cavernous Malformation. Nikola shares also dipped 10.4%. Meanwhile, Sify Technologies surged 103% after achieving a significant certification, and SPAR Group rose 65% following an acquisition agreement.

Portfolio Pulse from Avi Kapoor

September 03, 2024 | 5:41 pm

Dyne Therapeutics' stock dropped significantly after releasing new data from its Phase 1/2 DELIVER trial for DYNE-251, a drug for Duchenne muscular dystrophy. Despite showing higher dystrophin expression levels compared to Sarepta's EXONDYS 51, the stock fell by 31.90%.

Portfolio Pulse from Vandana Singh

September 03, 2024 | 4:37 pm

U.S. stocks fell with the Nasdaq down over 2% and the Dow Jones down over 1%. Sify Technologies surged 105% after achieving a significant certification, while SPAR Group rose 65% due to an acquisition agreement. Conifer Holdings gained 46% after selling its insurance agency operations. IO Biotech, Dyne Therapeutics, and Recursion Pharmaceuticals saw significant declines due to various announcements.

Portfolio Pulse from Avi Kapoor

September 03, 2024 | 4:00 pm

U.S. stocks fell with the Dow Jones down over 1% due to the ISM Manufacturing PMI missing estimates. Notable stock movements include Sify Technologies surging 110% and Dyne Therapeutics dropping 34% after clinical trial data release.

Portfolio Pulse from Avi Kapoor

September 03, 2024 | 2:19 pm

Several major stocks, including Dyne Therapeutics, Acadia Healthcare, and Boeing, are experiencing declines in pre-market trading. Dyne Therapeutics fell sharply after announcing new clinical data, while Boeing faces potential labor issues and a downgrade from Wells Fargo.

Portfolio Pulse from Avi Kapoor

September 03, 2024 | 12:03 pm

Dyne Therapeutics shares are trading lower following the announcement of new clinical data from its Phase 1/2 DELIVER trial of DYNE-251. The trial showed unprecedented dystrophin expression and functional improvement in patients with Duchenne muscular dystrophy amenable to exon 51 skipping.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:44 am

Dyne Therapeutics has released new clinical data from its Phase 1/2 DELIVER trial of DYNE-251, showing positive results in patients with Duchenne Muscular Dystrophy. The company plans to initiate registrational cohorts and aims for a registration update by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 10:32 am

Stifel analyst Paul Matteis maintains a Buy rating on Dyne Therapeutics (NASDAQ:DYN) and raises the price target from $41 to $66.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 12:50 pm

Guggenheim analyst Debjit Chattopadhyay maintains a Buy rating on Dyne Therapeutics (NASDAQ:DYN) and raises the price target from $45 to $50.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 5:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.